16 September 2021  
EMA/CHMP/501847/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Jyseleca 
filgotinib 
On 16 September 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Jyseleca. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 
The CHMP adopted a new indication as follows2: 
Ulcerative colitis 
Jyseleca is indicated for the treatment of adult patients with moderately to severely 
active ulcerative colitis who have had an inadequate response with, lost response to, or 
were intolerant to either conventional therapy or a biologic agent. 
For information, the full indications for Jyseleca will be as follows: 
Rheumatoid arthritis 
Jyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult 
patients who have responded inadequately to, or who are intolerant to one or more disease 
modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in 
combination with methotrexate (MTX). 
Ulcerative colitis 
Jyseleca is indicated for the treatment of adult patients with moderately to severely active 
ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant 
to either conventional therapy or a biologic agent. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
the marketing authorisation has been granted by the European Commission. 
Jyseleca  
EMA/CHMP/501847/2021 
Page 2/2 
 
 
 
